Peptide‐based targeted therapeutics and apoptosis imaging probes for cancer therapy
The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Peptides have advantages over antibodies in terms of deep tissue penetration, low immunogenicity, and cost-effective production, but they have short circulation time and poor stability in vivo. Peptides have been extensively used as targeting moieties for the delivery of drug-loaded nanoparticles and function as targeted therapeutics in cancer treatment. Here, we review peptides that are exploited as targeted therapeutics in cancer therapy and apoptosis imaging probes for the monitoring of treatment responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conceivable data revealed abolished PD‐1 and PD‐L1 interactions, improved T‐cell activity, and enhanced antitumor immunity in colon, breast, pancreatic, and kidney cancer models [338, 339, 340, 341].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [340]
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853 · cited 1×
“Probes that facilitate the visualization of apoptosis in vivo have pronounced significance for the assessment of treatment responses and drug screening (Adamczyk et al. 1998; Elmore 2007; Plati et al. 2011).”
BackgroundPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Caspase Functions in Cell Death and Disease
McIlwain, D. R., Berger, T., & Mak, T. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008656 · Cited by 2,594
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Anti-cancer activity of targeted pro-apoptotic peptides
Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., et al. (1999) · Nature Medicine · doi:10.1038/12469 · Cited by 936
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
Fife, B. T., Pauken, K. E., Eagar, T. N., Obu, T., Wu, J., Tang, Q., Azuma, M., Krummel, M. F., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1790 · Cited by 759
CD44 is required for two consecutive steps in HGF/c-Met signaling
Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P., & Ponta, H. (2002) · Genes & Development · doi:10.1101/gad.242602 · Cited by 518
Research works printed but not linked: 1
- Manish G, Vimukta S (2011) Targeted drug delivery system: a review. Res J Chem Sci 1:135–138
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Chiangjong, W., Chutipongtanate, S., & Hongeng, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5099 · Cited by 388
“Besides the aforementioned therapeutic peptides, peptides with specific cancer cell targets are applied to bind the cancer cell targets for cancer detection and therapy (216,217).”
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Self-citationPeptides as multifunctional players in cancer therapy
Vadevoo, S. M. P., Gurung, S., Lee, H.-S., Gunassekaran, G. R., Lee, S.-M., Yoon, J.-W., Lee, Y.-K., & Lee, B. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01016-x · Cited by 229
Self-citationAnti-cancer peptide-based therapeutic strategies in solid tumors
Karami Fath, M., Babakhaniyan, K., Zokaei, M., Yaghoubian, A., Akbari, S., Khorsandi, M., Soofi, A., Nabi-Afjadi, M., Zalpoor, H., Jalalifar, F., et al. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00332-w · Cited by 152
“Interleukin‐4 receptor CRKRLDRNC IL‐4Ra‐binding [197]”
Metadata
- Authors
- Vadevoo, S. M. P., Gurung, S., Khan, F., Haque, M. E., Gunassekaran, G. R., Chi, L., Permpoon, U., & Lee, B.
- Affiliations
- Kyungpook National University (KR)
- Venue
- Archives of Pharmacal Research
- Published
- 2019-02
- Volume
- 42
- Issue
- 2
- Pages
- 150-158
- ISSN
- 0253-6269 (ISSN-L)
- 1976-3786
- OpenAlex
- W2911952162
- Cited by
- 38
- References
- 68
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 9 · 2022: 5 · 2021: 4 · 2020: 6 · 2019: 4
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Archives of Pharmacal Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Research Foundation of Korea (2014R1A5A2009242, 2018R1A2B200837, 2017M3A9G8083382)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- peptide therapeutics, targeted cancer therapy, peptide delivery, drug-loaded nanoparticles, treatment response monitoring, cancer theranostics
- MeSH terms
- Amino Acid Sequence, Animals, Clinical Trials as Topic, Fluorescent Dyes, Humans, Neoplasms, Peptide Fragments, Drug Delivery Systems, Apoptosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peptide‐based targeted therapeutics and apoptosis imaging probes for cancer therapy. https://app.cochat.ai/papers/10.1007/s12272-019-01125-0
- The paper
- Vadevoo, S. M. P., Gurung, S., Khan, F., Haque, M. E., Gunassekaran, G. R., Chi, L., Permpoon, U., & Lee, B. (2019). Peptide‐based targeted therapeutics and apoptosis imaging probes for cancer therapy. Archives of Pharmacal Research. https://doi.org/10.1007/s12272-019-01125-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.